RxDoctor Payments Data

Sanjeev Wasan, MD

Gastroenterology · Lansdowne, VANPI 1093813990

Payments from drug & device makers

$6,653in general payments, 2019–2025

Across 401 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$686
  • Johnson & Johnson$514
  • Pfizer$369
  • Nestle Healthcare Nutrition Inc.$315
  • plus $2K from 27 others

What the payments were for

  • Consulting fees$240%
  • Food & beverage$6,57599%
  • Gifts$531%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,653 in reported general payments places this provider in the 60th percentile of 473 gastroenterology providers in Virginia.

See all gastroenterology providers in Virginia

Medicare billing

Part B allowed, 2024
$44,537
Medicare patients
164
Services billed
321

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase14$117,582
CreonLipase/Protease/Amylase13$91,626
LinzessLinaclotide44$46,617
Dexlansoprazole DrDexlansoprazole33$10,103
MotegrityPrucalopride Succinate11$5,731
Mesalamine ErMesalamine24$3,324
Pantoprazole Sodium289$3,263
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates50$3,066
Colesevelam Hcl12$2,673
Lubiprostone11$1,741
Omeprazole61$668
Lansoprazole14$623
Esomeprazole Magnesium11$240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,247$138,24357 claims
Aimmune Therapeutics, Inc.Zenpep$25$117,58214 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$686$5,73111 claims
SandozLansoprazole$23$62314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 473 gastroenterology providers in Virginia.

Other gastroenterology in Lansdowne

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →